BibTex format
@article{Hurrell:2022:10.1186/s13063-022-06652-8,
author = {Hurrell, A and Sparkes, J and Duhig, K and Seed, PT and Myers, J and Battersby, C and Clark, K and Green, M and Hunter, RM and Shennan, AH and Chappell, LC and Webster, L},
doi = {10.1186/s13063-022-06652-8},
journal = {Trials},
pages = {1--12},
title = {Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2)},
url = {http://dx.doi.org/10.1186/s13063-022-06652-8},
volume = {23},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BackgroundPre-eclampsia is a complex pregnancy disorder, characterised by new or worsening hypertension associated with multi-organ dysfunction. Adverse outcomes include eclampsia, liver rupture, stroke, pulmonary oedema, and acute kidney injury in the mother, and stillbirth, foetal growth restriction, and iatrogenic preterm delivery for the foetus. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing for suspected preterm pre-eclampsia has been incorporated into national guidance. The role of repeat PlGF-based testing and its effect on maternal and perinatal adverse outcomes have yet to be evaluated.MethodsThe PARROT-2 trial is a multi-centre randomised controlled trial of repeat revealed PlGF-based testing compared to repeat concealed testing, in women presenting with suspected pre-eclampsia between 22+0 and 35+6 weeks’ gestation. The primary objective is to establish whether repeat PlGF-based testing decreases a composite of perinatal severe adverse outcomes (stillbirth, early neonatal death, or neonatal unit admission). All women prior to enrolment in the trial will have an initial revealed PlGF-based test. Repeat PlGF-based tests will be performed weekly or two-weekly, depending on the initial PlGF-based test result, with results randomised to revealed or concealed.DiscussionNational guidance recommends that all women presenting with suspected preterm pre-eclampsia should have a single PlGF-based test when disease is first suspected, to help rule out pre-eclampsia. Clinical and cost-effectiveness of repeat PlGF-based testing has yet to be investigated. This trial aims to address whether repeat PlGF-based testing reduces severe maternal and perinatal adverse outcomes and whethe
AU - Hurrell,A
AU - Sparkes,J
AU - Duhig,K
AU - Seed,PT
AU - Myers,J
AU - Battersby,C
AU - Clark,K
AU - Green,M
AU - Hunter,RM
AU - Shennan,AH
AU - Chappell,LC
AU - Webster,L
DO - 10.1186/s13063-022-06652-8
EP - 12
PY - 2022///
SN - 1745-6215
SP - 1
TI - Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2)
T2 - Trials
UR - http://dx.doi.org/10.1186/s13063-022-06652-8
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000849222400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR - https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06652-8
UR - http://hdl.handle.net/10044/1/104794
VL - 23
ER -
